Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Nuclear pore protein NUP88 activates anaphase-promoting complex to promote aneuploidy
Ryan M. Naylor, … , Xiuqi Cao, Jan M. van Deursen
Ryan M. Naylor, … , Xiuqi Cao, Jan M. van Deursen
Published January 5, 2016
Citation Information: J Clin Invest. 2016;126(2):543-559. https://doi.org/10.1172/JCI82277.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 1

Nuclear pore protein NUP88 activates anaphase-promoting complex to promote aneuploidy

  • Text
  • PDF
Abstract

The nuclear pore complex protein NUP88 is frequently elevated in aggressive human cancers and correlates with reduced patient survival; however, it is unclear whether and how NUP88 overexpression drives tumorigenesis. Here, we show that mice overexpressing NUP88 are cancer prone and form intestinal tumors. To determine whether overexpression of NUP88 drives tumorigenesis, we engineered transgenic mice with doxycycline-inducible expression of Nup88. Surprisingly, NUP88 overexpression did not alter global nuclear transport, but was a potent inducer of aneuploidy and chromosomal instability. We determined that NUP88 and the nuclear transport factors NUP98 and RAE1 comprise a regulatory network that inhibits premitotic activity of the anaphase-promoting complex/cyclosome (APC/C). When overexpressed, NUP88 sequesters NUP98-RAE1 away from APC/CCDH1, triggering proteolysis of polo-like kinase 1 (PLK1), a tumor suppressor and multitasking mitotic kinase. Premitotic destruction of PLK1 disrupts centrosome separation, causing mitotic spindle asymmetry, merotelic microtubule-kinetochore attachments, lagging chromosomes, and aneuploidy. These effects were replicated by PLK1 insufficiency, indicating that PLK1 is responsible for the mitotic defects associated with NUP88 overexpression. These findings demonstrate that the NUP88-NUP98-RAE1-APC/CCDH1 axis contributes to aneuploidy and suggest that it may be deregulated in the initiating stages of a broad spectrum of human cancers.

Authors

Ryan M. Naylor, Karthik B. Jeganathan, Xiuqi Cao, Jan M. van Deursen

×

Figure 5

Nup98-Rae1 haploinsufficiency reveals premitotic APC/CCDH1 substrate selectivity for PLK1.

Options: View larger image (or click on image) Download as PowerPoint

Nup98-Rae1 haploinsufficiency reveals premitotic APC/CCDH1 substrate se...
(A) Western blot of G2-phase Nup98+/− Rae1+/− MEFs with or without MG132 treatment. (B) Western blot of nocodazole-arrested Nup98+/− Rae1+/− MEFs. (C) Images of G2 MEFs of the indicated genotypes immunostained for p-PLK1 (Thr210), γ-tubulin, and p-HH3 (Ser10). γ-Tubulin and p-HH3 (Ser10) were distinguished by subcellular compartmentalization. (D) Quantification of centrosomal p-PLK1 (Thr210) intensity of cells in C with or without MG132 treatment. (E) Same as in C. (F) Same as in D. (G) Western blot from RO-3306–treated or (H) nocodazole-arrested MEFs of the indicated genotypes. (I and J) Same as in G. DNA in C and E was visualized with Hoechst. Analyses in D and F were performed on 3 independent lines per genotype (at least 20 cells/line). Data represent the mean ± SEM. Western blots are representative of 3 independent experiments. Cyclin B1, cyclin A2, and actin blots from G and H are identical to those in Figure 4, K and L. Statistical significance was determined in D and F using a 2-tailed, unpaired t test. *P < 0.05. Scale bars: 10 μm. Nup88T indicates the combined transgenic lines 11 and 13.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
59 readers on Mendeley
See more details